Abstract 16635: Cost Effectiveness Analysis of the Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction REVIVED Trial Data
Carlos Chivardi(University of York), Pedro Saramago(University of York), Richard D. Evans(London School of Hygiene & Tropical Medicine), Christopher A. Rinaldi(St Thomas' Hospital), Holly Morgan(King's College London), Divaka Perera, Tim Clayton(London School of Hygiene & Tropical Medicine), Mark Sculpher(University of York), Peter O’Kane(Royal Bournemouth Hospital), M. J. Ryan(King's College London), Matthew Dodd(London School of Hygiene & Tropical Medicine), Mark C. Petrie(British Heart Foundation)
Cited by 0
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
|The Lancet Diabetes & Endocrinology|2019|1.6k
Current State of Knowledge on Aetiology, Diagnosis, Management, and Therapy of Peripartum Cardiomyopathy: A Position Statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy
|European Journal of Heart Failure|2010|1.1k
Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2018|716